Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus types I and II

被引:26
|
作者
Andersson, S [1 ]
Gessain, A
Taylor, GP
机构
[1] Swedish Inst Infect Dis Control, Dept Immunol, SE-17182 Stockholm, Sweden
[2] Inst Pasteur, Unite Oncol Virale, F-75728 Paris 15, France
[3] Imperial Coll Sch Med, Dept Genitourinary Med, London W2 1PG, England
关键词
HTLV-I; HTLV-II; antibody testing; pooling; seroepidemiology; assays;
D O I
10.1016/S0168-1702(01)00289-1
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We evaluated a straight forward pooling strategy for antibody screening of HTLV-I/II, using panels of sera from various parts of the world including a total of 43 HTLV-I and 54 HTLV-II positive specimens. Four antibody screening assays were included in the evaluation: the HTLV-I/II GE 80/81 (Murex Diagnostics), the HTLV-I/HTLV-II Ab Capture ELISA (Ortho Diagnostics), the HTLV-1/11 ELISA 3.0 (Genelabs Diagnostics) and the Serodia HTLV-I (Fujirebio). The Murex and Ortho assays represent a new generation of HTLV screening tests with a sandwich format incorporating both HTLV-I and HTLV-II synthetic and/or recombinant peptide antigens. The Genelabs assay is an indirect ELISA with recombinant HTLV-I and -II antigens and Serodia is a particle agglutionation assay with HTLV-I whole viral lysate. Each HTLV-positive sample was included in pools of 1/1 up to 1/16, in two-fold steps made in normal HTLV-negative blood donor ser-um from one up to nine donors. For HTLV-I, with the exception of one false negative sample in dilution 1/16 with Genelabs ELISA, all assays were positive at all dilutions. The Murex assay had absorbance values at maximum levels for all samples at all dilutions. The other assays had gradually decreasing absorbance values although clearly above cut-off. For HTLV-II, the Murex assay correctly detected all samples to dilution 1/16 despite gradually decreasing signals. The Serodia assay had 100% sensitivity to dilution 1/4 while at 1/8 and 1/16 it decreased 82 and 80%, respectively. The Genelabs ELISA had gradually decreasing sensitivity for HTLV-II from 98 (1/1) to 33% (1/16) while the Ortho assay detected all specimens at all dilutions in a limited set of samples tested. Taken together, this evaluation has shown that pooling of samples may be an appropriate strategy for serosurveillance of HTLV. It is, however, crucial to limit the number of samples and to choose assays that allow the dilution caused by the pooling. Using the best performing assays in this evaluation for pools of e.g. five samples would leave a reasonable safety margin. (C) 2001 Elsevier Science BN. All rights reserved.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 50 条
  • [21] Human T-cell lymphotropic virus type I and neurological diseases
    Nagai, M
    Osame, M
    JOURNAL OF NEUROVIROLOGY, 2003, 9 (02) : 228 - 235
  • [22] Detection of human T-cell lymphotropic virus type 1 in plasma samples
    Cabral, Fabio
    Arruda, Lia Barbara
    de Araujo, Marilia Ladeira
    Montanheiro, Patricia
    Smid, Jerusa
    Penalva de Oliveira, Augusto Cesar
    Duarte, Alberto J. S.
    Casseb, Jorge
    VIRUS RESEARCH, 2012, 163 (01) : 87 - 90
  • [23] Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: The retrovirus epidemiology donor study
    Schreiber, GB
    Murphy, EL
    Horton, JA
    Wright, DJ
    Garfein, R
    Chien, HC
    Nass, CC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 14 (03) : 263 - 271
  • [24] Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia
    Tamiya, S
    Matsuoka, M
    Etoh, KI
    Watanabe, T
    Kamihira, S
    Yamaguchi, K
    Takatsuki, K
    BLOOD, 1996, 88 (08) : 3065 - 3073
  • [25] INFECTION OF HUMAN T-LYMPHOTROPIC VIRUS-I-SPECIFIC IMMUNE T-CELL CLONES BY HUMAN T-LYMPHOTROPIC VIRUS-I
    MITSUYA, H
    JARRETT, RF
    COSSMAN, J
    COHEN, OJ
    KAO, CS
    GUO, HG
    REITZ, MS
    BRODER, S
    JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (05): : 1302 - 1310
  • [26] Absence of human T-cell lymphotropic virus type I and human foamy virus in thymoma
    H Li
    P J Loehrer
    M Hisada
    J Henley
    D Whitby
    E A Engels
    British Journal of Cancer, 2004, 90 : 2181 - 2185
  • [27] Management of coinfection with human immunodeficiency virus and human T-Cell lymphotropic virus type I
    Nadler, JP
    Bach, MC
    Godofsky, E
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (02) : 415 - 415
  • [28] Human T-cell lymphotropic virus types I and II infections in patients with leukaemia/lymphoma and in subjects with sexually transmitted diseases in Nigeria
    Olaleye, OD
    Ekweozor, CC
    Li, ZL
    Opala, IE
    Sheng, Z
    Onyemenem, TN
    Rasheed, S
    ARCHIVES OF VIROLOGY, 1996, 141 (02) : 345 - 355
  • [29] Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: A case-control study
    Gentile, G
    Mele, A
    Monarca, B
    Vitale, A
    Pulsoni, A
    Visani, G
    Castelli, G
    Rapicetta, M
    Verani, P
    Martino, P
    Mandelli, F
    Trematerra, M
    Villano, U
    Ferrigno, L
    Iantosca, G
    DaCas, R
    Bernasconi, C
    Merante, S
    Tura, S
    Colombini, R
    Capobianchi, A
    Rolli, M
    Donati, PPP
    Santilli, S
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1996, 5 (03) : 227 - 230
  • [30] HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND CUTANEOUS T-CELL LEUKEMIA/LYMPHOMA
    HALL, WW
    JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05): : 1581 - 1585